scholarly journals Implementation of Multiple Criteria Decision Analysis Approaches in the Supplier Selection Process: A Case Study

2016 ◽  
pp. 951-960 ◽  
Author(s):  
Dmitry Kisly ◽  
Anabela Tereso ◽  
Maria Sameiro Carvalho
Keyword(s):  
Decision Analysis ◽  
Supplier Selection ◽  
Selection Process ◽  
Multiple Criteria ◽  
Multiple Criteria Decision Analysis

Developing a multiple-criteria decision analysis for green economy transition: a Canadian case study

2019 ◽  
Vol 31 (4) ◽  
pp. 617-641 ◽  
Author(s):  
Mehdi Bagheri ◽  
Masood Sheikh Alivand ◽  
Mohammad Alikarami ◽  
Christopher A. Kennedy ◽  
Ganesh Doluweera ◽  
...  
Keyword(s):  
Decision Analysis ◽  
Multiple Criteria ◽  
Green Economy ◽  
Multiple Criteria Decision Analysis

SIGNED DISTANCED-BASED TOPSIS METHOD FOR MULTIPLE CRITERIA DECISION ANALYSIS BASED ON GENERALIZED INTERVAL-VALUED FUZZY NUMBERS

2011 ◽  
Vol 10 (06) ◽  
pp. 1131-1159 ◽  
Author(s):  
TING-YU CHEN
Keyword(s):  
Decision Analysis ◽  
Supplier Selection ◽  
Fuzzy Numbers ◽  
Multiple Criteria ◽  
Decision Makers ◽  
Multiple Criteria Decision Analysis ◽  
Topsis Method ◽  
Order Preference ◽  
Priority Order ◽  
Interval Valued

The theory of interval valued fuzzy sets is very valuable for modeling impressions of decision makers. In addition, it gives ability to quantify the ambiguous nature of subjective judgments in an easy way. In this paper, by extending the technique for order preference by similarity to ideal solution (TOPSIS), it is proposed a useful method based on generalized interval valued trapezoidal fuzzy numbers (GITrFNs) for solving multiple criteria decision analysis (MCDA) problems. In view of complexity in handling sophisticated data of GITrFNs, this paper employs the concept of signed distances to establish a simple and effective MCDA method based on the main structure of TOPSIS. An algorithm based on TOPSIS method is established to determine the priority order of given alternatives by using properties of signed distances. Finally, the feasibility of the proposed method is illustrated by a practical example of supplier selection.

scholarly journals Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden

2018 ◽  
Vol 3 (2) ◽  
pp. 238146831879621 ◽  
Author(s):  
Aris Angelis
Keyword(s):  
Prostate Cancer ◽  
Decision Analysis ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
Value Theory ◽  
Multiple Criteria ◽  
Decision Makers ◽  
Multiple Criteria Decision Analysis

Background. Multiple criteria decision analysis (MCDA) has been identified as a prospective methodology for assisting decision makers in evaluating the benefits of new medicines in health technology assessment (HTA); however, limited empirical evidence exists from real-world applications. Objective. To test in practice a recently developed MCDA methodological framework for HTA, the Advance Value Framework, in a proof-of-concept case study with decision makers. Methods. A multi-attribute value theory methodology was adopted applying the MACBETH questioning protocol through a facilitated decision-analysis modelling approach as part of a decision conference with four experts. Settings. The remit of the Swedish Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket [TLV]) was adopted but in addition supplementary value dimensions were considered. Patients. Metastatic castrate-resistant prostate cancer patients were considered having received prior chemotherapy. Interventions. Abiraterone, cabazitaxel, and enzalutamide were evaluated as third-line treatments. Measurements. Participants’ value preferences were elicited involving criteria selection, options scoring, criteria weighting, and their aggregation. Results. Eight criteria attributes were finally included in the model relating to therapeutic impact, safety profile, socioeconomic impact, and innovation level with relative importance weights 44.5%, 33.3%, 14.8%, and 7.4% per cluster, respectively. Enzalutamide scored the highest overall weighted preference value score, followed by abiraterone and cabazitaxel. Dividing treatments’ overall weighted preference value scores by their costs derived “costs per unit of value” for ranking the treatments based on value-for-money grounds. Limitations. Study limitations included lack of comparative clinical effects across treatments and the small sample of participants. Conclusion. The Advance Value Framework has the prospects of facilitating the evaluation process in HTA and health care decision making; additional research is recommended to address technical challenges and optimize the use of MCDA for policy making.

Sign in / Sign up

Export Citation Format

Share Document